New cocktail targets rare tumor in kids
NCT ID NCT01189643
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial adds three drugs—irinotecan, temozolomide, and bevacizumab—to the usual chemotherapy for newly diagnosed desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. The study includes 15 patients aged 1 to 30 and aims to see if the combination is safe and tolerable. Researchers will also check how well the tumor responds and track survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
irinotecan, temozolomide, and bevacizumab (chemotherapy drugs)
What this could lead to
If it works, this could point toward a more effective treatment for desmoplastic small round cell tumor, a rare and aggressive cancer.
What could go wrong
This is a very early pilot trial with only 15 participants, so results may not apply to all patients. The added drugs may cause more side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States